Envestnet Asset Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Envestnet Asset Management’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.22M	Buy	52,851 +5,235	+11%	+$167K	﹤0.01%	3070
2026 Q1	$1.26M	Buy	47,616 +7,786	+20%	+$228K	﹤0.01%	3325
2025 Q4	$1.15M	Sell	39,830 -1,985	-5%	-$59.6K	﹤0.01%	3186
2025 Q3	$1.16M	Sell	41,815 -5,921	-12%	-$150K	﹤0.01%	3245
2025 Q2	$1.16M	Sell	47,736 -22,593	-32%	-$495K	﹤0.01%	3191
2025 Q1	$1.46M	Sell	70,329 -2,380	-3%	-$59.8K	﹤0.01%	2941
2024 Q4	$1.71M	Sell	72,709 -11,384	-14%	-$280K	﹤0.01%	2798
2024 Q3	$2.15M	Sell	84,093 -8,054	-9%	-$205K	﹤0.01%	2606
2024 Q2	$2.16M	Sell	92,147 -1,056	-1%	-$26.6K	﹤0.01%	2553
2024 Q1	$2.68M	Sell	93,203 -22,285	-19%	-$670K	﹤0.01%	2384
2023 Q4	$3.79M	Buy	115,488 +13,489	+13%	+$367K	﹤0.01%	2074
2023 Q3	$2.84M	Sell	101,999 -2,528	-2%	-$82.6K	﹤0.01%	2160
2023 Q2	$3.56M	Sell	104,527 -314	-0.3%	-$9.87K	﹤0.01%	1913
2023 Q1	$3.15M	Buy	104,841 +3,331	+3%	+$103K	﹤0.01%	1911
2022 Q4	$2.87M	Sell	101,510 -20,498	-17%	-$651K	﹤0.01%	1936
2022 Q3	$4.01M	Sell	122,008 -3,369	-3%	-$124K	﹤0.01%	1645
2022 Q2	$3.95M	Sell	125,377 -5,528	-4%	-$193K	﹤0.01%	1656
2022 Q1	$6.01M	Buy	130,905 +5,736	+5%	+$273K	﹤0.01%	1488
2021 Q4	$7.67M	Sell	125,169 -15,973	-11%	-$1.1M	﹤0.01%	1339
2021 Q3	$10.5M	Sell	141,142 -15,201	-10%	-$1.28M	0.01%	1116
2021 Q2	$14.5M	Buy	156,343 +19,248	+14%	+$1.64M	0.01%	935
2021 Q1	$12.2M	Buy	137,095 +45,322	+49%	+$4.5M	0.01%	940
2020 Q4	$8.56M	Buy	91,773 +58,063	+172%	+$4.63M	0.01%	982
2020 Q3	$2.15M	Buy	33,710 +26,271	+353%	+$1.54M	﹤0.01%	1582
2020 Q2	$388K	Buy	+7,439	New	+$319K	﹤0.01%	2556
2019 Q4	–	Sell	-8,110	Closed	-$239K	–	3076
2019 Q3	$239K	Buy	8,110 +1,984	+32%	+$64.5K	﹤0.01%	2776
2019 Q2	$211K	Buy	+6,126	New	+$196K	﹤0.01%	2858

Other funds holding ARKG

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Envestnet Asset Management's ARKG Position: Q2 2026 in Review

Envestnet Asset Management increased its ARK Genomic Revolution ETF (ARKG) stake by 11% in Q2 2026, buying an estimated $167K and bringing the position to 52,851 shares worth $2.22M. The position accounts for ﹤0.01% of the portfolio, ranked #3070.

Envestnet Asset Management first reported a position in ARKG in Q2 2019 and has held it in 27 quarters since. The position peaked at $14.5M in Q2 2021. 271 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

Envestnet Asset Management held 52,851 shares of ARK Genomic Revolution ETF worth $2.22M as of Q2 2026.
Envestnet Asset Management bought 5,235 ARK Genomic Revolution ETF shares in Q2 2026, an estimated $167K.
ARK Genomic Revolution ETF made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #3070 holding.
Envestnet Asset Management first reported a position in ARK Genomic Revolution ETF in Q2 2019 and has held it in 27 quarters since.
Envestnet Asset Management's ARK Genomic Revolution ETF position peaked at $14.5M in Q2 2021.
271 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.